Back to top

Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating

Analyst Tim Chiang of Capital One Financial maintained a Buy rating on Amphastar Pharmaceuticals (AMPH – Research Report), retaining the price targ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Amphastar Pharmaceuticals, Inc. (AMPH)